Betahistine, tablets 8 mg 30 pcs

Pharmacological group: Histamine drug

ATCode: N07CA01

Pharmacological properties:

Pharmacodynamics. Agonist of H₁-histamine receptors of the inner ear vessels and antagonist of H₃-histamine receptors of the vestibular nuclei of the CNS. By relaxing the precapillary sphincters of the vessels of the inner ear, it improves blood circulation in the vascular band of the inner ear.

Dose-dependently reduces the generation of action potentials in the neurons of the lateral and medial vestibular nuclei.

Accelerates recovery of vestibular function after unilateral vestibular neurectomy by accelerating and facilitating central vestibular compensation (due to antagonism with H3-histamine receptors).

It alleviates symptoms in Meniere’s syndrome and vestibular vertigo. Stable therapeutic effect occurs after 14 days.

Pharmacokinetics. Absorbed rapidly, binding to plasma proteins is less than 5%. Maximum concentration in plasma is after 3 hours. The elimination half-life is in 3-4 hours.

Metabolized to inactive metabolites: 2-pyridylacetic acid (the main metabolite) and dimethylbetahistine. 85-90% is excreted by the kidneys as 2-pyridylacetic acid within 24 hours. Excretion of betahistine and dimethylbetahistine by the kidneys is insignificant. The intestine excretes only a small portion of betahistine and its metabolites.

Indications

• Treatment of Meniere’s syndrome, characterized by vertigo (accompanied by nausea and vomiting), hearing loss and tinnitus.
• Symptomatic treatment of vestibular vertigo.
  

Active ingredient

Betahistine

Composition

Active ingredient: Betahistine dihydrochloride – 8 mg excipients: microcrystalline cellulose 68 mg, lactose monohydrate 50 mg, crosspovidone 7.0 mg, magnesium stearate 1.4 mg, povidone 4.2 mg, colloidal silicon dioxide (aerosil) 1.4 mg.

How to take, the dosage

The drug is prescribed orally, with meals.

Adults and elderly patients:

Tablets 8 mg: 1-2 tablets 3 times daily.

Tablets 16 mg: 1/2-1 tablet 3 times daily.

Tablets 24 mg: 1 tablet 2 times a day .

The improvement is usually noted at the beginning of therapy, stable therapeutic effect occurs after two weeks of treatment and may build up over several months of treatment. Treatment is prolonged. The length of time we have to take the drug is determined individually.

In patients with renal and/or hepatic impairment, there are no data about the need to change therapeutic doses.

Interaction

Histamine receptor blockers reduce the effect of betahistine.

Special Instructions

Therapeutic effect in some cases builds up within a few months from the start of treatment.
Betahistine has no sedative effect and does not affect the ability to drive or operate machinery.

Contraindications

Hypersensitivity, pregnancy, lactation, childhood.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Pheochromocytoma.

With caution:

Gastric or 12 duodenal ulcer (history), bronchial asthma. These patients should be monitored regularly during treatment.

Side effects

Nausea, vomiting, dyspepsia, abdominal pain, bloating, urticaria, itching, rash, angioedema, headache.

Overdose

Symptoms: nausea, vomiting, headache, facial hyperemia, dizziness, tachycardia, decreased BP, bronchospasm; drowsiness (at doses up to 640 mg); at a dose of 728 mg there were reports of convulsions. Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

There is insufficient data to evaluate the effect of the drug during pregnancy and lactation. In this regard, it is not recommended to take the drug during pregnancy. Breast-feeding should be stopped during treatment.

Similarities

Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista, Vertran